NOVO Fibre-tab
Natural health product licensed in Canada
- Licence holder
- Teva Canada Limited
- NPN or DIN-HM
- 80042720
- Status
- Active licence
- Licence date
- 7 June 2013
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- TPD Cat IV/LS
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Avena sativa Source : Enveloppe | 125 mg | Not calculated |
Non-medicinal ingredients
Dioxyde de silicium colloïdal, Povidone, Cellulose microcristalline, Sorbate de potassium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes et enfants | minimum: 12 years | minimum: 4 Comprimé ; maximum: 12 Comprimé | 1 Tous les jours |
Uses authorised in Canada
For gentle relief of constipation.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Do not use in the presence of abdominal pain, nausea, fever or vomiting. Do not take any type of laxative for more than one (1) week, unless instructed by your physician. A laxative should not be taken within 2 hours of another medicine because the desired effect of the other medicine may be reduced. If you are experiencing a sudden change in bowel habits that has persisted for more than 2 weeks, undiagnosed rectal bleeding, or have failed to defaecate following the use of a bulk-forming laxative product, consult a health care practitioner prior to use. If symptoms worsen or if laxative effect does not occur within seven days, consult a health care practitioner. If you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking this product, consult a health care practitioner immediately. If you are taking medications which inhibit peristaltic movement, consult a health care practitioner prior to use (e.g. opioids, loperamide). If you are pregnant or breastfeeding, consult a healthcare practitioner prior to use. Do not use if you have difficulty swallowing .
Source
Official Health Canada record, licence 80042720
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.